Pat Adams
@PathologyPat
Regional Oncology Specialist @ Exact Sciences Minimal Residual Disease Monitoring
Excited to see this masterpiece out @Nature today. In this study, @JannaHeide, @AndrasPiffko, @ErnstLengyel & colleagues @OvCa_UChicago unraveled molecular mechanisms of NNMT in ovarian cancer and developed a specific inhibitor. A highly promising therapeutic avenue.
Proud to share our new @Nature study: We developed the 1st NNMT inhibitor that reprograms cancer-associated fibroblasts, boosting immune response & stopping tumor growth in ovarian cancer models, especially when paired with immunotherapy. @OvCa_UChicago nature.com/articles/s4158…
Developing serum proteomics based prediction models of disease progression in ADPKD | Nature Communications nature.com/articles/s4146…
We turned medicinal chemistry into a card game, which takes 3-10 years to play. PDF: jabde.com/wp-content/upl…
Disintermediating PBM middlemen would save Americans $100b a year says USC research. They nailed it academic.oup.com/healthaffairss…
If you have a proton center at your institution…..🙏🏻consider enrolling patients on these proton trials to help us learn more for our ☢️ #radonc patients! @NRGonc
Distinct Mitochondrial DNA Deletion Profiles in Pediatric B- and T-ALL During Diagnosis, Remission, and Relapse mdpi.com/1422-0067/26/1…
TAF1 is required for fetal but not adult hematopoiesis in mice: Developmental Cell cell.com/developmental-…
NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling | Nature Genetics nature.com/articles/s4158…
There are much more structural variants within our genomes than previously conceived, >26,000 per person nature.com/articles/s4158… nature.com/articles/s4158…
ICYMI: Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies brnw.ch/21wUoBP @Elvin_Wag
Not all ovarian tumors are primary. Dr. Lauren Schwartz explains how to spot metastatic cancers hiding in plain sight — and why it matters for patient care. 👉 ow.ly/V2jI50Wg3Ce #Pathology #GynecologicPathology #OvarianCancer #Metastasis #ThePathologist
T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below nature.com/articles/s4158…
Choroid Plexus Tumors -Papilloma, Ki67 <5% -Atypical papilloma, Ki67~10% -Carcinoma, Ki67~20% Dr. Ballester #USCAP25 #PathX #pathology
A Long Post About Pathology Boards I need to emphasize that this is based on my personal experience, which will most likely be totally different from others'. Here's a thread 🧵: #pathology #PathTwitter #PathX #PathBoards
Spotlight on #TAMs & Immune Cells 🔍 What’s covered: Role of TAMs in cancer progression & #immune suppression Interactions with T cells, NK cells & dendritic cells 📖 Full articl: oaepublish.com/articles/2394-…
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations ow.ly/Pho750WrZxm #lymphoidneoplasia #specialreports
🚨Just out in @CCR_AACR our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC We analyzed 5 major trials 👉 Early relapse: up to 83% of all recurrences🤯 1/ 🧵 Why this matters 👇 🔗 Full article: doi.org/10.1158/1078-0…
🆕review in press: Clinical challenges and proposed solutions for patients with invasive lobular breast cancer @ChristineDesme2 doi.org/10.1016/j.anno…
From @JAMA_current: Approximately 21 000 women are diagnosed with ovarian cancer annually in the US. This Review summarizes the diagnosis and management of high-grade serous ovarian cancer. ja.ma/44I2mv9
Migrating immune cells globally coordinate protrusive forces | Nature Immunology nature.com/articles/s4159…